[ad_1]
Webcast on Wednesday, April 3RD 10:10 a.m. ET
La Jolla, California, March 28, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”) is a biotechnology company developing an innovative pipeline of natural killer T (NKT) cell modulators for therapeutic use Inflammatory, fibrotic and autoimmune diseases. announced that GRI Bio CEO Dr. Marc Hertz will speak at the MedInvest Biotech and Pharmaceutical Investor Conference in New York City on Wednesday, April 3, 2024, at 10:10 a.m. ET.
In addition to the presentation, management will participate in one-on-one meetings with members of the accredited investor community who have registered for the conference. For more information about the conference, please visit the conference website.
A live webcast of the event will be available on the events page of the Investors section of the Company’s website (www.gribio.com).
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company working to fundamentally change the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, key regulators early in the inflammatory cascade, to interrupt disease progression and return the immune system to homeostasis. NKT cells are innate T cells that have the characteristics of NK and T cells and are the functional link between the innate immune response and the adaptive immune response. iNKT cells play a critical role in the propagation of damage, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity being developed as a novel oral therapy for the treatment of IPF, a serious disease with unmet need. The company is also developing a series of novel type 2 NKT agonists for the treatment of SLE. In addition, GRI Bio has a library of over 500 proprietary compounds with the ability to power a growing pipeline.
Investor contact information:
JTC TEAM LLC
Jenny Thomas
(833)475-8247
GRI@jtcir.com
[ad_2]
Source link